文献速递血液淋巴病理

未治疗原发扁桃体弥漫大B细胞淋巴瘤长期无瘤生存的临床病理特征

[Clinicopathological features of long-term tumor-free survival of patients with untreated primary tonsillar diffuse large B-cell lymphoma].
PubMed 文献 · Zhonghua Bing Li Xue Za Zhi · 2019-01-01

回顾性分析80例原发扁桃体DLBCL会诊病例,其中10例未放化疗长期无瘤生存者为实验组、70例已治疗者为对照组。未治疗组病变多局限扁桃体、结构仅部分破坏、EBER及t(14;18)阴性、基因重排单克隆;两组年龄、bcl-2、CMYC及共表达差异有统计学意义,中位总生存期81与20个月差异无统计学意义。

要点

  • 未放化疗长期无瘤生存的原发扁桃体DLBCL病变多局限扁桃体,扁桃体结构仅部分破坏。
  • 该组EBER与t(14;18) FISH均阴性,基因重排检测为单克隆。
  • 未治疗组与已治疗组中位总生存期81与20个月,差异无统计学意义。

核心结论

  • 未放化疗而长期无瘤生存的原发扁桃体DLBCL具有相对独特的临床和病理学特征。
  • 未治疗组与已治疗组预后无显著差异,提示可能不需要放化疗,从而避免相关副作用。

研究设计与样本

  • 回顾性分析首都医科大学附属北京友谊医院病理科2006年4月至2017年7月原发扁桃体DLBCL会诊病例共80例。
  • 未放化疗而长期无瘤生存者10例为实验组,已治疗患者70例为对照组,分析临床资料、组织学、免疫组化及分子生物学结果。

主要发现

  • 患者年龄6~79岁,平均46.5岁,男性37例、女性43例。
  • 未治疗组病变大部分局限在扁桃体,切除活检显示结构仅部分破坏、病变比较新鲜,EBER和FISH检测t(14;18)均为阴性,基因重排检测为单克隆。
  • 未治疗组与已治疗组在年龄、bcl-2表达、CMYC蛋白表达及CMYC和bcl-2共表达方面差异有统计学意义(P<0.05)。
  • 两组在性别、部位、分型、临床分期方面差异无统计学意义(P>0.05)。
  • 未治疗组和已治疗组中位总生存期分别为81及20个月,差异无统计学意义(P>0.05)。

关键数值与推荐

  • 年龄<40岁患者中,未治疗组在部位和CMYC蛋白表达方面与已治疗组相比差异有统计学意义(P<0.05),其他方面差异均无统计学意义(P>0.05)。

临床怎么用

  • 对原发扁桃体DLBCL中病变局限、结构仅部分破坏、EBER及t(14;18)阴性且基因重排单克隆者,可考虑密切观察而非立即放化疗。
  • 决策时需结合年龄、bcl-2与CMYC表达及共表达情况综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinicopathological features of long-term tumor-free survival in patients with untreated primary diffuse large B-cell lymphoma (DLBCL) of the tonsil. Methods: The study included 80 consultation cases of primary tonsillar DLBCL from April 2006 to July 2017 in the Department of Pathology, Beijing Friendship Hospital, Capital Medical University. The patients were divided into two groups: experimental groups of 10 untreated patients with long-term tumor-free survival, and 70 patients who had been treated (control group). The clinical data, histopathological features, immunohistochemical staining, and molecular biology test results of the patients were analyzed retrospectively. Results: Patients who had long-term tumor-free survival with untreated primary diffuse large B-cell lymphoma had the disease mostly confined to the tonsil. Biopsy showed that the tonsil structure was only partially effaced and the lesions were relatively "fresh". EBER and FISH test for t (14;18) results were negative. Gene rearrangement detection showed monoclonality. There was statistically significant difference between the age, bcl-2 expression, CMYC protein expression and co-expression of CMYC and bcl-2 between the untreated group and the treated group(P<0.05). Patient gender, tumor site, histological type and clinical stage showed no difference between the untreated group and the treated group (P>0.05); The median overall survival of the untreated group and treated group was 81 months and 20 months, respectively, and the difference was not statistically significant (P>0.05).In patients younger than 40 years of age, the untreated group had a statistically significant difference in primary site and CMYC protein expression compared with the treated group (P<0.05), and there was no statistical significance in other aspects. Conclusions: Long-term tumor-free survival patients with untreated tonsillar primary DLBCL have relatively unique clinical characteristics. There is no significant difference in the prognosis between the untreated and treated groups, indicating radiotherapy and chemotherapy may not be required and therefore, avoiding related side effects. 目的: 探讨未放化疗而长期无瘤生存原发扁桃体弥漫性大B细胞淋巴瘤(DLBCL)的临床和病理学特征。 方法: 收集首都医科大学附属北京友谊医院病理科2006年4月至2017年7月间,原发扁桃体DLBCL的会诊病例共80例,其中未放化疗而长期无瘤生存者10例为实验组,已治疗患者70例为对照组,对患者的临床资料、病理组织学、免疫组织化学染色及分子生物学检测结果进行回顾性分析。 结果: 患者年龄6~79岁,平均年龄46.5岁,男性37例,女性43例。未放化疗而长期无瘤生存的DLBCL,病变大部分局限在扁桃体,切除活检显示结构仅部分破坏,病变比较新鲜,EB病毒编码的小RNA(EBER)检测和荧光原位杂交(FISH)检测t(14;18)结果均为阴性;基因重排检测为单克隆。未放化疗组在年龄、bcl-2表达、CMYC蛋白表达以及CMYC和bcl-2共表达方面与已治疗组相比,差异具有统计学意义(P<0.05);在性别、部位、分型、临床分期等方面,两者间差异无统计学意义(P>0.05);未放化疗组和已治疗组中位总生存期分别为81及20个月,差异无统计学意义(P>0.05)。在年龄<40岁的患者中,未放化疗组在部位和CMYC蛋白表达方面与已治疗组相比,差异有统计学意义(P<0.05),其他各方面差异均无统计学意义(P>0.05)。 结论: 未放化疗而长期无瘤生存的原发扁桃体DLBCL具有相对独特的临床和病理学特征。生存分析结果显示未放化疗组可长期无瘤生存,可以使患者免受放疗和化疗带来的副作用。.

来源:Zhonghua Bing Li Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang XJ, Zhou XG, Wei J, et al. [Clinicopathological features of long-term tumor-free survival of patients with untreated primary tonsillar diffuse large B-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi. 2019. PMID: 31104674. doi:10.3760/cma.j.issn.0529-5807.2019.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。